Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This ...
Looking for novel anticancer agents, researchers from Ho Chi Minh City University of Science (Vietnam) and colleagues recently identified KTt-45, a compound derived from 6-prenylnaringenin, as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results